Retriever Medical

Executive Summary

Retriever Medical is a private medical device company developing the ClotHound™ thrombectomy system for the treatment of deep vein thrombosis (DVT). The company's technology specifically targets sub-acute and chronic, wall-adherent clot, which constitutes the majority of real-world DVT cases yet remains poorly addressed by existing mechanical thrombectomy devices. The ClotHound system integrates mechanical clot engagement with integrated distal embolic protection, aiming to improve safety and efficacy in challenging clot removal. Founded in 2016 and based in San Jose, California, Retriever Medical is currently in the pre-clinical stage with no disclosed funding or valuation. The company's focus on a significant unmet need and its differentiated approach position it as a promising player in the cardiovascular device space, though it faces typical early-stage risks including capital requirements and clinical validation.

Upcoming Catalysts (preview)

• TBDInitiation of First-in-Human Clinical Study60% success
• Q3 2026Receipt of FDA Breakthrough Device Designation70% success
• Q3 2026Close of Series A Financing Round50% success